Image

Global Kidney Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Kidney Disease Market, By Indication (Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Others), Treatment (Medication, Dialysis, Surgery, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Kidney Disease Market

Kidney Disease Market Analysis and Size

The global kidney disease market is expected to witness significant growth during the forecast period. As per the reports of the CDC, it is expected that more than 37 million people in the U.S. suffer from CKD, whereas globally, more than 500 million people are affected. An increasing number of patients suffering from kidney failure is projected to drive the market.

Data Bridge Market Research analyses a growth rate in the global kidney disease market in the forecast period 2022-2029. The expected CAGR of the global kidney disease market tends to be around 5.50% in the mentioned forecast period. The market was valued at USD 96.72 billion in 2021, and it would grow up to USD 148.43 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Kidney Disease Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Indication (Acute Kidney Injury, Chronic Kidney Disease, End-Stage Renal Disease, Others), Treatment (Medication, Dialysis, Surgery, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (Ireland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)

Market Opportunities

  • Increased Demands For Blood Tests
  • Increasing Demand for Hospitals

Market Definition

Kidney disease damages the nephron, unable for the kidney to function to remove the waste product from the body. The disease can cause other severe problems such as hypertension, kidney failure, brain aneurysm, and chronic pain. Other symptoms include blood in urine, kidney stones, urinary tract or kidney infections, and back or side pain. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become a massive public health issue.   

Global Kidney Disease Market Dynamics

Drivers

  • Increased Incidence of Kidney Diseases

The rising incidence of chronic kidney disease globally is majorly responsible for boosting the growth of the global renal drugs market. According to the National Kidney Foundation records, nearly 10% of the global population is affected by chronic kidney disease (CKD). As per WHO facts 2019, about 1.13 billion people worldwide have hypertension. In 2014–2016, diabetes and hypertension were responsible for around 75% of kidney failure. Thus, it boosts market growth.

  • Technological Advancements

There have been many advances concerning diagnostic and treatment procedures that are boosting the market growth. For instance, in April 2020, FMCNA established the National Intensive Renal Care Reserve, which comprised devices that can deliver CRRT, IHD, and SLED/PIRRT. Any such conditions that cause reduced kidney function lead to chronic kidney disease (CKD), which may develop over a period and lead to end-stage renal kidney disease where the kidney can no longer function independently.

Opportunities

  • Increased Demands For Blood Tests

Among the major tests, the foremost test for the diagnosis of kidney disease includes a blood test, which helps understand how well the kidneys work. It measures levels of a waste product called creatinine in the blood. Furthermore, the demand for these tests is projected to increase as the incidence of CKD is high and growing in many parts of the world. The global incidence of end-stage renal disease (ESRD) is high and growing at a significant rate. Thus, it creates more opportunities for market growth.

  • Increasing Demand for Hospitals

The presence of a large number of hospitals in the U.S., combined with a well-developed healthcare infrastructure, is another factor contributing to market growth. For instance, as per the American Hospital Association, there were around 208 federal government hospitals,  6,090 community hospitals, and 625 nonfederal psychiatric hospitals in the U.S. Major increase in the number of hospital admissions for acute kidney disease is boosting the demand for dialysis as well as transplant, thereby boosting the market growth.

 Restraints/Challenges

  • Side Effects of Kidney DiseaseDrugs

The side effects associated with these renal drugs could reduce the growth of the global renal drugs market over a forecast period. Effects such as loss of appetite, fever, and rashes, can hamper the market growth.

  • High Cost

The huge expenditure associated with these agents hampers the market growth. Treatments that include corticosteroids, ACE inhibitors, diuretics, and immunosuppressive therapy impede the market's growth.

This global kidney disease market market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global kidney disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Kidney Disease Market            

The growing cases of COVID-19 directly correlate with the growth of kidney-related diseases. For instance, as per the report published in 2021, titled "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4–37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% among hospitalized COVID-19 patients. Thus, it has been found that the COVID-19 virus is having a major impact on the kidney of patients, which in turn, is expected to increase the burden of kidney disorders shortly and boost the market growth. Thus, COVID-19 had a major impact on the global kidney disease market.

Recent Developments

  • In October 2019, Fresenius Medical Care received breakthrough device designation by the U.S. FDA for its latest hemodialysis machine, which aims to stop blood clotting without using any medication.

Global Kidney Disease Market Scope

The global kidney disease market is segmented on the basis of indication, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

 

Indication

  • Acute Kidney Injury
  • Chronic Kidney Disease,
  • End-Stage Renal Disease
  • Others

Treatment

  • Medication
  • Dialysis
  • Surgery
  • Others

Route of Administration

  • Oral
  • Parenteral

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Kidney Disease Market Regional Analysis/Insights

The global kidney disease market is analysed and market size insights and trends are provided by indication, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the globalkidney diseasemarket report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Europe has been witnessing the highest growth for the global kidney disease market throughout the forecasted period due to increasing initiatives by the government and pharmaceutical organizations to spread awareness and the presence of generic manufacturers.

North America dominates the market due to the advancement of technology for kidney diseases and increasing initiatives by pharmaceutical organizations to generate novel formulations.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Globalkidney Disease Market Share Analysis

The global kidney disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to globalkidney diseasemarket.

Key players operating in the global kidney disease market include:

  • Pfizer Inc (U.S.)
  • AstraZeneca (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Allergan,Inc (Ireland)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Ltd (India)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Cipla Inc (India)
  • Aurobindo Pharma (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott (U.S.)

 

 


SKU-
Why Choose Us


Frequently Asked Questions

The Kidney Disease Market is projected to grow at a CAGR of 5.50% during the forecast period by 2029.
The future market value of the Kidney Disease Market is expected to reach USD 148.43 billion by 2029.
The major players in the Kidney Disease Market are Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (Ireland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), etc.
The countries covered in the Kidney Disease Market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, etc.